Buy the Book PDA Download

Update Me E-mail alerts The Merck Manual Minute

Print This Topic Email This Topic

Gestational trophoblastic disease is proliferation of trophoblastic tissue in pregnant or recently pregnant women. Manifestations may include excessive uterine enlargement, vomiting, vaginal bleeding, and preeclampsia, particularly during early pregnancy. Diagnosis includes measurement of the β subunit of human chorionic gonadotropin, pelvic ultrasonography, and confirmation by biopsy. Tumors are removed by suction curettage. If disease persists after removal, chemotherapy is indicated.

Gestational trophoblastic disease is a tumor originating from the trophoblast, which surrounds the blastocyst and develops into the chorion and amnion (see Conception and Prenatal Development). This disease can occur during or after an intrauterine or ectopic pregnancy. If the disease occurs during a pregnancy, spontaneous abortion, eclampsia, or fetal death typically occurs; the fetus rarely survives. Some forms are malignant; others are benign but behave aggressively.

Pathology

Classification is morphologic:

• Hydatidiform mole: In this abnormal pregnancy, villi become edematous (hydropic), and trophoblastic tissue proliferates.
• Chorioadenoma destruens (invasive mole): The myometrium is invaded locally by a hydatidiform mole.
• Choriocarcinoma: This invasive, usually widely metastatic tumor is composed of malignant trophoblastic cells and lacks hydropic villi; most of these tumors develop after a hydatidiform mole.
• Placental site trophoblastic tumor: This rare tumor consists of intermediate trophoblastic cells that persist after a term pregnancy; it may invade adjacent tissues or metastasize.

Hydatidiform moles are most common among women < 17 or > 35 and those who have had previous gestational trophoblastic disease. They occur in about 1/2000 gestations in the US. For unknown reasons, incidence in Asian countries approaches 1/200. Most (> 80%) hydatidiform moles are benign. The rest may persist, tending to become invasive; 2 to 3% of hydatidiform moles are followed by choriocarcinoma.

Symptoms and Signs

Initial manifestations of a hydatidiform mole suggest early pregnancy, but the uterus often becomes larger than expected within 10 to 16 wk gestation. Commonly, women test positive for pregnancy, have vaginal bleeding and severe vomiting, and fetal movement and fetal heart sounds are absent. Passage of grapelike tissue strongly suggests the diagnosis. Complications may include uterine infection, sepsis, hemorrhagic shock, and preeclampsia, which may occur during early pregnancy.

Placental site trophoblastic tumors tend to cause bleeding.

Choriocarcinoma usually manifests with symptoms due to metastases.

Gestational trophoblastic disease does not impair fertility or predispose to prenatal or perinatal complications (eg, congenital malformations, spontaneous abortions).

Diagnosis

• Serum β-hCG
• Pelvic ultrasonography

Gestational trophoblastic disease is suspected in women with a positive pregnancy test and any of the following:

• Uterine size much larger than expected for dates
• Symptoms or signs of preeclampsia
• Passage of grapelike tissue
• Suggestive findings (eg, mass containing multiple cysts instead of a fetus) seen during ultrasonography done to evaluate pregnancy
• Unexplained metastases in women of child-bearing age
• Unexpectedly high levels of human chorionic gonadotropin (β-hCG) detected during pregnancy testing
• Unexplained complications of pregnancy

If gestational trophoblastic disease is suspected, testing includes measurement of serum β-hCG and pelvic ultrasonography. Findings (eg, very high β-hCG levels, classic ultrasonographic findings) may suggest the diagnosis, but biopsy is required. Invasive mole and choriocarcinoma are suspected if biopsy findings suggest invasive disease or if β-hCG levels remain higher than expected after treatment for hydatidiform mole (see below).

Treatment

• Tumor removal by suction curettage
• Further evaluation for persistent disease and spread of tumor
• Chemotherapy for persistent disease
• Posttreatment contraception for persistent disease

Hydatidiform mole, invasive mole, and placental site trophoblastic tumor are evacuated by suction curettage. Alternatively, if childbearing is not planned, hysterectomy may be done.

After tumor removal, gestational trophoblastic disease is classified clinically to determine whether additional treatment is needed. The clinical classification system does not correspond to the morphologic classification system. Invasive mole and choriocarcinoma are classified clinically as persistent disease. The clinical classification is used because both are treated similarly and because exact histologic diagnosis may require hysterectomy.

Table 5
WHO Scoring System in Metastatic Gestational Trophoblastic Disease Prognostic Factor Description Score† Age (yr) < 40 ≥40 0 1 Preceding pregnancy Mole Abortion Term 0 1 2 Interval (mo)* < 4 ≥ 4 and < 7 ≥ 7 and < 13 ≥ 13 0 1 2 4 Pretreatment serum hCG (IU/mL) < 1000 1000−<10,000 10,000−<100,000 ≥ 100,000 0 1 2 4 Largest tumor, including any uterine tumors 3−<5 cm ≥ 5 cm 1 2 Site of metastases Lungs Spleen, kidneys GI tract Brain, liver 0 1 2 4 Number of metastases identified 1−4 5−8 > 8 1 2 4 Number of chemotherapy drugs used unsuccessfully 1 ≥ 2 2 4 *Between the end of the preceding pregnancy and the start of chemotherapy. †Total score is obtained by adding the score for each prognostic factor: ≤ 6 = low risk ≥ 7= high risk Adapted from FIGO Oncology Committee: FIGO staging for gestational trophoblastic neoplasia 2000. International Journal of Gynaecology and Obstetrics 2002; 77(3):285–287.

A chest x-ray is taken, and serum β-hCG is measured. If the β-hCG level does not normalize within 10 wk, the disease is classified as persistent. Persistent disease requires CT of the brain, chest, abdomen, and pelvis. Results dictate whether disease is classified as nonmetastatic or metastatic. In metastatic disease, prognosis (including risk of death) may be poor or good (see Table 5: Gynecologic Tumors: WHO Scoring System in Metastatic Gestational Trophoblastic Disease). Poor prognosis is suggested by the following (National Institutes of Health [NIH] criteria):

• Urinary hCG excretion > 100,000 IU in 24 h
• Duration of disease > 4 mo (interval since prior pregnancy)
• Brain or liver metastases
• Disease after full-term pregnancy
• Serum hCG > 40,000 mIU/mL
• Unsuccessful prior chemotherapy
• WHO score > 8

Persistent disease is usually treated with chemotherapy. Treatment is considered successful if at least 3 consecutive serum β-hCG measurements at 1-wk intervals are normal. Typically, oral contraceptives (any is acceptable) are given for 6 to 12 mo; alternatively, any effective contraceptive method can be used.

Nonmetastatic disease can be treated with a single chemotherapy drug ( methotrexate Some Trade Names
RHEUMATREX
Click for Drug Monograph
or dactinomycin Some Trade Names
COSMEGEN
Click for Drug Monograph
). Alternatively, hysterectomy is considered for patients > 40 or those desiring sterilization and may be required for those with severe infection or uncontrolled bleeding. If single-drug chemotherapy is ineffective, hysterectomy or multidrug chemotherapy is indicated. Virtually 100% of patients with nonmetastatic disease can be cured.

Low-risk metastatic disease is treated with single-drug or multidrug chemotherapy. High-risk metastatic disease requires aggressive multidrug chemotherapy. Cure rates are 90 to 95% for low-risk and 60 to 80% for high-risk disease.

Hydatidiform mole recurs in about 1% of subsequent pregnancies. Patients who have had a mole require ultrasonography early in subsequent pregnancies, and the placenta should be sent for pathologic evaluation.

Last full review/revision November 2008 by David M. Gershenson, MD; Pedro T. Ramirez, MD

Content last modified November 2008